Work Here?
BillionToOne
Work Here?
Molecular diagnostics for prenatal and oncology testing
BillionToOne
Work Here?
Molecular diagnostics for prenatal and oncology testing
About BillionToOne
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Series D
Total Funding
$380.2M
Headquarters
Menlo Park, California
Founded
2016
Overview
BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne's business model centers on providing these diagnostic services directly to healthcare providers, generating revenue through the sale of testing services that inform treatment decisions. The goal of BillionToOne is to enhance the accuracy, efficiency, and accessibility of molecular testing, driven by a commitment to growth, equality, and teamwork in making a positive impact on healthcare.
Simplify's Take
What believers are saying
- BillionToOne achieved over 100% revenue growth, reaching $153 million in 2024.
- The company secured a billion-dollar valuation with a $130 million funding round.
- Expansion in Austin, Texas, will create 1,000 jobs and increase production capacity.
What critics are saying
- Emerging startups in molecular diagnostics could erode BillionToOne's market share.
- Rapid technological advancements require continuous innovation to maintain competitiveness.
- Economic instability in target markets may affect product affordability and adoption.
What makes BillionToOne unique
- BillionToOne's QCT technology detects DNA variations at single base-pair resolution.
- Their non-invasive prenatal tests replace risky procedures like amniocentesis.
- Northstar products offer precise therapy selection and monitoring for oncology patients.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$380.2M
Above
Industry Average
Funded Over
6 Rounds
Y CombinatorIndustry standards
Benefits
Competitive pay
Retirement savings package
Parental leave
Free snacks & lunches
Medical, dental, & vision premiums
On campus perks
Free-on-site EV charging
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 2%Company Announces Record Financial Results at 43rd Annual J.P. Morgan Healthcare ConferenceMENLO PARK, Calif., Jan. 28, 2025 /PRNewswire/ -- BillionToOne , a next-generation molecular diagnostics company, announced record financial results at this year's J.P. Morgan Healthcare Conference in San Francisco. In 2024, the company's revenue reached $153 million, more than doubling from $72 million in 2023.BillionToOne's success has been driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S."We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne
2021, 2022 ve 2023 yıllarında en yüksek yatırım alan yerli girişimleri sizlere aktarmıştık. Bir yılın daha sonuna gelirken, 2024 yılında en yüksek yatırımları alan yerli girişimleri derledik. Geçtiğimiz yılın en çok yatırım alan 10 yerli girişimiyle kıyaslandığında bu yıl yatırım miktarlarının yükseldiği görülmekte. Aslında 2022 yılından 2023 yılına gelindiğinde yatırım miktarlarında bir düşüş ile karşılaşılmıştı. Bu durumun 2024 yılında değiştiğini söylemek mümkün. Geçen yıl 105 milyon dolar ile listedeki en yüksek yatırımı alan Insider, bu yıl aldığı 500 milyon dolar ile çıtayı yükseltirken zirvedeki yerini korudu
MENLO PARK, Calif., Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 14, 2025.BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years.This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows:Location: Mission Bay (32nd Floor) at The WestinDate: Tuesday, January 14, 2025Time: 2:30-2:55 pm PTA webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone
BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards.
Molecular diagnostics firm BillionToOne broke ground Wednesday on a 220,000-sq-ft facility in Austin, TX, that is expected to bring 1,000 jobs to the city.
BillionToOne is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About BillionToOne
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Series D
Total Funding
$380.2M
Headquarters
Menlo Park, California
Founded
2016
BillionToOne is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today